Business Overview: Solid Biosciences Inc. (NASDAQ: SLDB)

---

Executive Summary

Solid Biosciences Inc. is a clinical-stage life sciences company developing genetic medicines for rare, fatal neuromuscular and cardiac diseases. The company traces back to 2013 (originally organized as SOLID Ventures Management, LLC), converted to a Delaware corporation and took its current name in 2018, and is headquartered in Charlestown, Massachusetts.

Solid has no approved products and no commercial revenue — it is a pure clinical-stage biotech. Its significance comes from its lead program, SGT-003, an AAV-based microdystrophin gene therapy for Duchenne muscular dystrophy (DMD), which entered a pivotal Phase 3 trial (IMPACT DUCHENNE) with first dosing expected in April 2026. SGT-003 is one of only a small number of DMD gene therapies advancing toward a second generation of the category, following Sarepta Therapeutics' ELEVIDYS, the first and so far only approved DMD gene therapy.

Solid is well-capitalized for a clinical-stage company, ending the first half of 2026 with roughly $378 million in cash and investments, which management guides will fund operations into mid-2028 — covering the pivotal Phase 3 readout window for its lead asset.

---

1. Core Business Model & How They Work

Solid does not yet generate product revenue. Its business model is the standard biotech value-creation chain — discover, prove safety and efficacy in the clinic, win approval, then commercialize — financed along the way by equity capital markets and, distinctively for Solid, by out-licensing its proprietary gene-therapy delivery platform to other developers before any of its own products reach market.

[ Capsid & Platform Discovery ] ➡️ [ IND-Enabling / Preclinical ] ➡️ [ Phase 1/2 Clinical Trials ] ➡️ [ Pivotal Phase 3 ] ➡️ [ Regulatory Approval ] ➡️ [ Commercial Launch ]
                     │
                     └──➡️ [ Platform Out-Licensing to Third Parties ] ➡️ [ Upfront + Milestone + Royalty Revenue ]

Key Operational Drivers

1. Platform-first R&D: Solid's core technology is its POLARIS-101 AAV capsid, originally developed for its own DMD program but now licensed broadly. The company reports more than 50 agreements (executed licenses and related arrangements) with other organizations, carrying potential future milestone payments of $97.1 million as of December 31, 2025 — a rare example of a pre-commercial biotech generating licensing economics from its own research infrastructure.
2. Deep academic in-licensing: Solid builds its pipeline on intellectual property in-licensed from universities (Washington, Missouri, Florida, University of Pennsylvania) and collaborations such as Mayo Clinic, reducing the need to build every piece of underlying science in-house.
3. Capital-markets dependency: As a clinical-stage company with no product revenue, Solid funds its ~$100 million-plus annual cash burn through equity raises (e.g., a $226 million net-proceeds offering in March 2026) rather than operating cash flow.
4. Contract manufacturing reliance: Solid uses transient transfection manufacturing for its lead candidates and depends on third-party cGMP contract manufacturers for clinical supply, rather than owning commercial-scale manufacturing today.

---

2. Product Portfolio & Pipeline

Solid is a single-segment clinical-stage company (no reported revenue segments), so its franchises are best understood through its pipeline rather than a business-segment breakdown.

---

3. Competitive Landscape

           DMD GENE-THERAPY COMPETITIVE POSITION
   ┌──────────────────────────────────────────────────┐
   │ High                                              │
   │  ▲        [Sarepta - ELEVIDYS]                    │
   │  │        (approved, first-mover, but under       │
 R │  │         active FDA safety scrutiny)             │
 E │  │                                                 │
 G │  │                      [Solid Biosciences]        │
 U │  │                      (SGT-003, Phase 3,         │
 L │  │                       one reported Grade 3       │
 A │  │                       myositis event)            │
 T │  │                                                 │
 O │  │   [Exon-skipping / HDAC inhibitor / gene-editing │
 R │  │    competitors - non-gene-therapy alternatives]  │
 Y │ Low                                                │
   │  └───────────────────────────────────────────────► │
   │   Low     CLINICAL MATURITY / COMMERCIAL STAGE  High│
   └──────────────────────────────────────────────────┘

Competitors by Franchise

Duchenne Muscular Dystrophy

• Key competitor: Sarepta Therapeutics (ELEVIDYS), the first and only approved DMD gene therapy, giving Sarepta a multi-year commercial head start, physician familiarity, and payer-coverage precedent.
• Dynamics: In 2025, the FDA opened an investigation after three patient deaths (two from acute liver failure in DMD patients, one in a related limb-girdle muscular dystrophy trial using a similar AAVrh74 capsid) tied to Sarepta's gene therapies, and asked Sarepta to pause shipping — which Sarepta initially refused. This episode cuts both ways for Solid: it raises the bar of regulatory and safety scrutiny for the entire DMD gene-therapy class (including SGT-003, which has itself reported a Grade 3 immune-mediated myositis event), but it also creates an opening for a differentiated, cleaner safety profile to win share if SGT-003's Phase 3 data read out well.
• Other DMD approaches — exon-skipping therapies, HDAC inhibitors, and emerging gene-editing programs — compete for the same patient population with non-AAV mechanisms and different risk/benefit trade-offs.

Friedreich's Ataxia

• Key competitor: Biogen (Skyclarys), an approved small-molecule (not gene) therapy that has already established itself as standard-of-care, meaning SGT-212 must prove a meaningfully better disease-modifying benefit to displace an entrenched, already-reimbursed treatment.

CPVT

• Key competitor: Cardurion Pharmaceuticals, with a small-molecule candidate in Phase 2 — a fundamentally different (and likely lower-risk, easier-to-administer) therapeutic modality than Solid's gene-therapy approach.

---

4. Strategic Strengths & Risks

Strengths (The Moat)

• Platform out-licensing economics: Few clinical-stage, pre-revenue biotechs generate real licensing cash flow from their core technology; Solid's 50+ POLARIS-101 licensing arrangements and $97.1 million in potential milestones is a genuine, unusual asset.
• Deep, diversified academic IP network: Relationships spanning multiple universities and Mayo Clinic reduce single-point-of-failure risk in Solid's underlying science.
• First mover into Phase 3 behind an approved comparator: Unlike many biotechs racing to be first, Solid can design its Phase 3 program and commercial strategy with the benefit of Sarepta's real-world safety and efficacy experience (including its adverse events) already visible.

Risks

• Gene-therapy class safety overhang: The FDA's 2025 investigation into fatal liver failure linked to Sarepta's AAV gene therapies has raised regulatory scrutiny across the entire DMD gene-therapy category; SGT-003's own reported Grade 3 myositis event means Solid is not immune to this overhang.
• Single-asset concentration (near-term): Despite pipeline diversification into FA and cardiac disease, the vast majority of near-term investor and regulatory attention — and cash burn — is tied to SGT-003's Phase 3 outcome.
• Continued dilution risk: With a ~$112 million net loss in the first half of 2026 alone and no near-term product revenue, Solid will likely need further capital raises beyond its stated mid-2028 runway if SGT-003 is delayed.
• Manufacturing scale-up risk: Reliance on transient transfection and third-party contract manufacturers for clinical supply means Solid has not yet proven it can manufacture at commercial scale and quality.

---

5. Financial Overview

---

6. Summary Conclusion

Solid Biosciences is a clinical-stage gene-therapy company whose near-term fate is tied almost entirely to SGT-003's Phase 3 readout in Duchenne muscular dystrophy — a race it enters not as a first mover, but as a well-funded second mover with the advantage (and shadow) of watching Sarepta's ELEVIDYS experience, including its 2025 fatal safety events, play out in real time. The company's platform-licensing business and diversifying pipeline into Friedreich's ataxia and cardiac gene therapy provide optionality beyond DMD, and its ~$378 million cash position buys real runway. But the single biggest forward risk is straightforward: DMD gene therapy as a category is now under heightened regulatory and safety scrutiny, and Solid's own lead asset has already reported a serious adverse event — making the Phase 3 safety and efficacy data, expected over the next two years, the central event for the company's prospects.